DOCSLIB.ORG

Phosphodiesterases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phosphodiesterases www.aladdin-e.com Address:800 S Wineville Avenue, Ontario, CA 91761,USA Website:www.aladdin-e.com Email USA: [email protected] Email EU: [email protected] Email Asia Pacific: [email protected] Phosphodiesterases Cyclic nucleotide phosphodiesterases (PDEs) cAMP signaling operating in such cells. catalyze the hydrolysis of cAMP and/or cGMP. For various PDEs, located immediately N- They function with adenylyl and guanylyl terminal to the catalytic unit are family-specific cyclases to regulate the amplitude and duration paired regulatory domains. These allow of responses triggered by the second regulation through cross-talk with various other messengers, cAMP and cGMP. In doing so they signal transduction systems by either regulate a wide range of biological responses phosphorylation or allosteric regulation. triggered by light, hormones, neurotransmitters and odorants. Two classes of functional PDEs, PDEs are named to identify isoforms. Thus, which do not share any sequence homology, are HSPDE4A1 refers to the Homo sapiens PDE4 recognized: Class I PDEs, found in all eukaryotic family, gene A, splice variant 1. The high level of cells and Class II PDEs, found in lower sequence conservation among species, distinct eukaryotes. intracellular targeting and kinetic and regulatory There are 11 different mammalian PDE families characteristics suggest that individual PDEs play of which PDE4, PDE7 and PDE8 are specific for particular roles in specific physiological cAMP, while PDE5, PDE6 and PDE9 are specific processes. For example, PDE1 isoforms have for cGMP and others hydrolyze both cAMP and twin regulatory domains that allow them to bind cGMP. PDE3, whose Vmax cAMP > Vmax cGMP and be activated by Ca2+/calmodulin, providing and Km cGMP < Km cAMP, is generally cross talk between the Ca2+ and cAMP/cGMP considered as a cGMP-inhibited cAMP signaling pathways. They can participate in the hydrolyzing PDE. feed-forward amplification of neuronal signals. PDEs contain a conserved, catalytic domain of PDE2 has twin regulatory GAF domains that around 250 amino acids, where an invariant allow binding and activation by cGMP, providing glutamine provides the key specificity cross talk with the cGMP/NO signaling pathway. determinant by scanning the purine moiety in Indeed, PDE2A plays a role in regulating cAMP/cGMP. Adjacent residues anchor this aldosterone production in adrenal glomerulosa glutamine in different orientations so as to define cells through integration of cAMP and cGMP specificity for either or both cAMP/cGMP. signals. PDE3, which hydrolyzes cAMP, has a unique insert in its catalytic region, which Twenty-one genes encode the 11 known PDE attenuates its cGMP hydrolyzising capacity such families with additional isoform diversity that cGMP potently inhibits cAMP hydrolysis by generated through alternative mRNA splicing and this enzyme. This allows elevation of cGMP to the use of distinct promoters. Isoforms have an potentiate cAMP signals, which has functional extreme N-terminal domain that uniquely significance in regulation of platelet aggregation. characterizes them. In various PDE families, and PDE3B underpins the anti-lipolytic action of particularly with PDE4, this is involved in insulin in adipocytes through being intracellular targeting. Different cell types express phosphorylated and activated by PKB/Akt. PDE3, a unique complement of PDE isoforms, thereby together with PDE4 isoforms, provide the major individually tailoring the nature of the spatial and cAMP hydrolyzing activity in many cells. PDE4 kinetic characteristics of the cAMP signal. This isoforms underpin much of compartmentalized defines the characteristics of compartmentalized cAMP signaling by interacting with a range 1 www.aladdin-e.com of scaffold proteins, including barrestin, AKAPs, modulation of cGMP hydrolysis subsequent to SRC, kinases, myomegalin and RACK1. Their activation by GTP-bound transducin. The phosphorylation by ERK configures cross-talk functional significance of the newer PDEs is not with this pathway and phosphorylation by PKA well appreciated and they provide a challenge for promotes cAMP desensitization. Chemical and the future in understanding their physiological genetic knockout identifies PDE4s as having a roles. key role in inflammatory responses, memory and depression. PDE5, has cGMP-binding, regulatory The Table below contains accepted modulators GAF domains and plays a role in regulating and additional information. For more information smooth muscle tension in certain vascular beds. and a complete list of the related products, please Sildenafil, a selective PDE5A inhibitor, is used to click: Aladdin treat erectile dysfunction. PDE6 plays a central role in visual phototransduction through rapid Family Name PDE1 PDE2 PDE3 PDE4 PDE5 Known 1A, 1B, 1C 2A 3A, 3B 4A, 4B, 4C, 4D 5A Genes Descriptive CaM-dependent PDE cGMP- cGMP-inhibited cAMP-specific PDE cGMP-binding Name stimulated PDE PDE PDE 1141 aa Structural 535 aa (human) 941 aa (human) 647 aa (human) 874 aa (human) (human) Information HSPDE1A3 HSPDE2A3 HSPDE4A1 HSPDE5A1 HSPDE3A1 cGMP PKA Regulators Ca2+/CaM Insulin ERK PKG Leptin , Phosphatidic acid Substrate cAMP or cAMP or cAMP or cAMP cGMP Specificity cGMP cGMP cGMP *Cilostamide *Sildenafi Enoximone *Rolipram *Vardenafil Vinpocetine *EHNA Inhibitors Imazodan *Ro20-1724 Dipyridamole SCH-51866 *BAY60-7550 Trequinsin *RP 73401 T-1032 Milrinone Zaprinast Heart Lung Adrenal cortex Major Tissue Brain, heart, smooth Adipose Platelets Brain Many tissues Expression muscle, olfactory cilia Pancreas Smooth muscle Heart Platelets Corpus collusum Regulates monocyte, macrophage T-cell, eosinophil, neutrophil function Sperm development Regulates neuronal function and maturation β2/β3 regulation and differentiation Monocyte/macrophage of cardiac Platelet function Vascular smooth Physiological Regulates functions of differentiation myocytes Adipocyte muscle cell Function inflammatory cells and Olfactory neuron Endothelial cell function relaxation vascular smooth muscle cells regulation function Pro-apoptotic Neuronal regulation Anti-apoptotic Endothelial cell function Inhibition of bone loss Intermittent Airway inflammation (asthma, Penile erectile claudication COPD) dysfunction Fertility peripheral Rheumatoid arthritis Disease Heart disease Asthma Inflammation arterial occlusive Crohn's disease Relevance Anti-angiogenic COPD Olfaction disease Learning Pulmonary Restenosis Memory hypertension Obesity Schizophrenia 2 www.aladdin-e.com Type-2 diabetes Spinal cord injury Migraine Stroke Restenosis Chronic B-cell lymphocytic leukemia Spinal cord injury Parkinson's Disease Anti-angiogenic Osteopenia (including osteoporosis) Family Name PDE6 PDE7 PDE8 PDE9 PDE10 PDE11 Known Genesa 6A, 6B 7A, 7B 8A, 8B 9A 10A 11A High affinity High affinity Descriptive Photoreceptor cAMP- Dual specificity Dual specificity cAMP- cGMP- Name PDE specific PDE PDE PDE specific PDE specific PDE Structural 860 aa (human) 482 aa (human) 713 aa (human) 593 aa (human) 779 aa (human) 490 aa (human) Informationb HSPDE6A1 HSPDE7A1 HSPDE8A1 HSPDE9A1 HSDPE10A1 HSPDE11A1 Regulators Light Not Known Not Known Not Known PKA Not Known Substrate cAMP or cAMPor cGMP cAMP cAMP cGMP Specificity cGMP cGMP SCH-51866d c Zaprinast d Zaprinast Inhibitors BRL50481 Dipyridamole SCH-51866 Zaprinast Dipyridamole Dipyridamole Dipyridamole Rod and cone Testis Major Tissue Skeletal muscle Testis Skeletal muscle Photoreceptor Liver Kidney Expression T-cells Brain Prostate Outer segments Thyroid Sperm function Physiological Visual signal Thyroid function Striatal neuron Not Known Not Known (motility, Function transduction T-cell activation function number) Parkinsonism Schizophrenia Hyperthyroidism Disease Retinitis Obsessive Metabolic bone Fertility Fertility Relevance pigmentosa compulsive disease disorders Addictions Abbreviations trimethoxyphenyl)-3-isoquinoline carboxylate CaM: Calmodulin sulfate EHNA: Erythro-9-(2-hydroxy-3-nonyl)adenine PKA: cAMP-dependent protein kinase b: bovine PKG: cGMP-dependent protein kinase h: human Ro 20-1724: 4-[(3-Butoxy-4- m: mouse methoxyphenyl)methyl]2-imidazolidinone r: rat RP 73401: N-(3,5-Dichloropyrid-4-yl)-3- cyclopentyloxy-4-methoxybenzamide References SB-207499: c-4-Cyano-4-(3-cyclopentyloxy-4- Baillie, G.S., et al., beta-Arrestin-mediated PDE4 methoxyphenyl-r-1-cyclohexane carboxylic acid) cAMP phosphodiesterase recruitment regulates SCH-51866: cis-5,6a,7,8,9,9a-Hehahydro-2-[4- beta-adrenoceptor switching from Gs to Gi., Proc (trifluoromethyl)phenylmethyl]-5-methyl- Natl. Acad. Sci. USA, 100, 940-945 (2003). cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one Beavo, J.A. and Brunton, L.L., Cyclic nucleotide T-1032: Methyl-2-(4-aminophenyl)-1,2-dihydro-1- research - still expanding after half a century., oxo-7-(2-pyridinylmethoxy)-4-(3,4,5- Nat. Rev. Mol. Cell Biol., 3, 710-718 (2002). 3 www.aladdin-e.com Conti, M., et al., Cyclic AMP-specific PDE4 Acad. Sci. USA, 99, 13260-13265 (2002). phosphodiesterases as critical components of Masciarelli, S., et al., Cyclic nucleotide cyclic AMP signaling., J. Biol. Chem., 278, 5493- phosphodiesterase 3A-deficient mice as a model 5496 (2003). of female infertility., J. Clin. Invest., 114, 196-205 Francis, S.H., et al., Cyclic nucleotide (2004). phosphodiesterases: relating structure and Maurice, D.H., et al., Cyclic nucleotide function., Prog. Nucleic Acid Res. Mol. Biol., 65, phosphodiesterase activity, expression, and 1-52 (2001). targeting in cells of the cardiovascular system., Gresele, P., et al., Anti-platelet therapy:
Load more

Recommended publications
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target
    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells
    Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. K Matousovic, … , E N Chini, T P Dousa J Clin Invest. 1995;96(1):401-410. https://doi.org/10.1172/JCI118049. Research Article We studied interactions between the mitogen-activated protein kinase (MAPK) signalling pathway and cAMP-protein kinase (PKA) signaling pathway in regulation of mitogenesis of mesangial cells (MC) determined by [3H]thymidine incorporation, with or without added EGF. Forskolin or dibutyryl cAMP strongly (by 60-70%) inhibited [3H]thymidine incorporation into MC. Cilostamide, lixazinone or cilostazol selective inhibitors of cAMP-phosphodiesterase (PDE) isozyme PDE-III, inhibited mitogenesis to similar extent as forskolin and DBcAMP and activated in situ PKA, but without detectable increase in cAMP levels. Cilostamide and cilostazol were more than three times more effective at inhibiting mesangial mitogenesis than rolipram and denbufylline, inhibitors of isozyme PDE-IV, even though PDE-IV was two times more abundant in MC than was PDE-III. On the other hand, when incubated with forskolin, rolipram-enhanced cAMP accumulation was far greater (10-100x) than with cilostamide. EGF increased MAPK activity (+300%); PDE isozyme inhibitors which suppressed mitogenesis also inhibited MAPK. PDE isozyme inhibitors also suppressed PDGF-stimulated MC proliferation. We conclude that cAMP inhibits the mitogen-dependent MAPK-signaling pathway probably by decreasing the activity of Raf-1 due to PKA-catalyzed phosphorylation. Further, we surmise that minor increase in the cAMP pool metabolized by PDE-III is intimately related to regulation of mesangial proliferation. Thus, PDE isozyme inhibitors have the potential to suppress MC proliferation by a focused effect upon signaling pathways.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Phosphodiesterase Inhibitors: Their Role and Implications
    International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes.
    [Show full text]
  • Phosphodiesterases, 3',5'-Cyclic Nucleotide (Pdes) (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F260/2019.4 Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Chen Yan1 1. University of Rochester, USA Abstract 3',5'-Cyclic nucleotide phosphodiesterases (PDEs, 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3',5'-cyclic nucleotide (usually cyclic AMP or cyclic GMP). isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2',3'-cyclic nucleotide 3'-phosphodiesterase (E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS. Contents This is a citation summary for Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond
    International Journal of Molecular Sciences Review Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond Tatiana M. Vinogradova * and Edward G. Lakatta Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, National Institute of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA; [email protected] * Correspondence: [email protected] Abstract: The sinoatrial (SA) node is the physiological pacemaker of the heart, and resting heart rate in humans is a well-known risk factor for cardiovascular disease and mortality. Consequently, the mechanisms of initiating and regulating the normal spontaneous SA node beating rate are of vital importance. Spontaneous firing of the SA node is generated within sinoatrial nodal cells (SANC), which is regulated by the coupled-clock pacemaker system. Normal spontaneous beating of SANC is driven by a high level of cAMP-mediated PKA-dependent protein phosphorylation, which rely on the balance between high basal cAMP production by adenylyl cyclases and high basal cAMP degradation by cyclic nucleotide phosphodiesterases (PDEs). This diverse class of enzymes includes 11 families and PDE3 and PDE4 families dominate in both the SA node and cardiac myocardium, degrading cAMP and, consequently, regulating basal cardiac pacemaker function and excitation-contraction coupling. In this review, we will demonstrate similarities between expression, distribution, and colocalization of various PDE subtypes in SANC and cardiac myocytes of different species, including humans, focusing on PDE3 and PDE4. Here, we will describe specific targets of the coupled-clock pacemaker system modulated by dual PDE3 + PDE4 activation and provide Citation: Vinogradova, T.M.; Lakatta, evidence that concurrent activation of PDE3 + PDE4, operating in a synergistic manner, regulates the E.G.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Inhibition of PDE3B Augments PDE4 Inhibitor-Induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia1
    Vol. 8, 589–595, February 2002 Clinical Cancer Research 589 Inhibition of PDE3B Augments PDE4 Inhibitor-induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia1 Eunyi Moon, Richard Lee, Richard Near, benefit in a subset of relatively PDE4-inhibitor resistant Lewis Weintraub, Sharon Wolda, and CLL patients. Adam Lerner2 INTRODUCTION Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts 02118 [E. M., R. L., Methylxanthines such as theophylline, a drug widely used R. N., L. W., A. L.]; Department of Pathology, Boston University for treatment of asthma and neonatal apnea, induce apoptosis in School of Medicine, Boston, Massachusetts 02118 [A. L.]; and ICOS CLL3 cells in vitro (1). The sensitivity of CLL cells to other Corporation, Bothell, Washington 98021 [S. W.] agents that raise cAMP levels such as dibutyryl cAMP or forskolin has suggested that the proapoptotic activity of meth- ABSTRACT ylxanthines may arise, at least in part, because of their activity as nonspecific cyclic nucleotide PDE inhibitors (2). A Phase II Purpose: cAMP phosphodiesterase (PDE) 4 is a family clinical trial by Binet et al. (3) in patients with chlorambucil- of enzymes the inhibition of which induces chronic lympho- resistant CLL, as well as case reports (4), have suggested that cytic leukemia (CLL) apoptosis. However, leukemic cells adding theophylline to chlorambucil may be of clinical value in from a subset of CLL patients are relatively resistant to this disease. The efficacy of theophylline as a single agent in treatment with the PDE4 inhibitor rolipram, particularly early stage CLL is currently being examined by Makower et al.
    [Show full text]